However let's ths fool inhxishereshort post meaningless jabber over and over, think they have an agenda? Nah....please read quickly before deleted.
His article overstates and draws a conclusion on non basis, all management did was re-iterate
guidance, which was late 2015/early 2016. No conclusion can be made. AF is good at misleading
From today......Obama also will ask for $755 million in new, mandatory multi-year spending, mainly for the NIH. The money would be spent on developing vaccines, genomic analysis, early cancer detection tests, and cancer immunotherapy and combination therapy research.
Combo therapy has been the CLDX approach for sometime now. They have been a leader in advocating for combo therapy.
Federal govt. is now putting its weight beyond immunotherapy for brain cancer and combo therapy.
Rintega will be brought to MKRT rapidly.
Vicotori - Original Phase I trial at Duke (in 2004) - 50% OS at 24 months
Then, Phase 2 OS summary
Activate - Phase II at Duke - 53% OS at 24 months
Act II - Phase II - 44% OS at 24 months
Act III - Phase II - 52% OS at 24 months
Compared to Control = 6% OS at 24 months
To add, Long term follow up of three Phase II (Activate, Act II, Act III) studies (total 105 patients) = 14% 5 year survival rate (updated 2014).
That is 15 patients still alive after 5 years out of 105 patients.
Just imagine, 12 years ago the first trial was started at Duke, and the results have been consistent through three Phase 2 trials.
12 years later and how many GBM patients have died, while this drug could have extended overall survival for most, and for about 15% extended their life beyond 5 years, perhaps longer.
While, the current treatment bevacizumab (Avastin) shows no significant improvement in OS.
For all the bashers, know your facts.
The guys has been posting they same several stupid emails for some period of time; however the account shows him as a new user as of today, and has past same posts on this message board are gone ?
Hmmm....I know you are stupid, but are you real ?
Based on the REACT results, and consistent with immunotherapy drugs, it is apparent that the difference
compared to the control gets better over time (i.e. the tail effect). Rindo passed the first interim analysis at 50% of events (with a tough p ratio to meet), then just by simple comparison to the REACT pattern and results, I would expect the second interim analysis results to be better !!
I think this runs very quickly to $23 to $25, maybe up to $27, by the first week in January.
My guess is second interim analysis results around Jan 11
Jeez what a moron. Some of the stupidest post have see on this board. Seems like a 30 something who has 10K invested think he is the damn nuts
GBM patients have good Christmas present with the second interim analysis.
Bet you a liberal....
Help me understand, the first interim look this summer was powered at a P value of less than 0.003, that seems like a very high hurdle compared to the p value necessary for 75% of events, estimated to be determined late 2015 early 2016.
I think chance for achieving this p value at 75% is very high, considering the " survival tail" observed with the REACT data,
Putting those two together = very good news
Oppenheimer had them listed as a presenter, they screwed up.....so CLDS should take a 10% haircut because some jack legs lists them as presenting
Amazing data and information. All others in the field way behind. In a different market climate, this would have been on the order of a 75 to 100 percent a day gain.
But so what !!! I am paying for kds college with this one. I added some Dec 2015 options to a large position. I believe they will raise money before the end of year, current share price reflects some dilutive financing vehicle, already baked in.
But partnership, look out !!
Even I there is dilutive financing, I think share price goes up on news.
12 month price target is 15 to 20
But nick they actually found the WMDs in Iraq. End of 2014. I know liberal media will not report that, but wow intelligence that BUSH acted on was right all along.
And another.......With the AUGMENT treatment, the patients’ combined clinical pregnancy rates increased at least five-fold